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A number of crop products generated by using biotech-
nology have been introduced to the marketplace. These
biotechnology products have been carefully evaluated
for their overall safety from an agronomic, environmen-
tal, performance, and equivalence perspective, and the
safety of the newly expressed protein(s). One aspect of
the safety evaluation is the question concerning poten-
tial allergenicity. The allergy risk to consumers from
crops enhanced through biotechnology may be placed
into one of three categories. The first category involves
the transfer of a known allergen or cross-reacting aller-
gen into a food crop. The second risk category is the
potential for increasing the allergenicity of a crop by
increasing the expression of endogenous allergens. The
last category involves expression of transgenic proteins
that may become allergens de novo. Approaches to
identifying potential food allergens for purposes of safety
assessment have been developed and modified over the
past 15 years. However, no single factor has been recog-
nized as the primary indicator for the allergenic poten-
tial of proteins, and no validated animal model that is
predictive of protein allergenicity is currently available.
Therefore, the evaluation of protein allergenicity is cur-
rently based upon a ‘weight of evidence’ approach,
which takes into account a variety of factors that have
been associated with allergens, such as stability to pep-
sin digestion or other enzymes in vitro, glycosylation
status, food processing effects, protein abundance in the
crop, homology to known allergens, and the safety of
the gene(s) source. In addition, as part of the ‘weight-of-
evidence’ assessment, the biotechnology crop product
endogenous allergen levels are compared to those of its
non-biotechnology comparator to make sure that the
transformation does not impact known endogenous
allergens naturally present in the host crop. This presen-
tation will provide a general introduction and overview
of the current ‘state of the art’ for evaluating potential
allergenicity of biotechnology crop products.
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